A zinc-containing compound, Polaprezinc, is effective for patients with taste disorders: randomized, double-blind, placebo-controlled, multi-center study

Sakagami, Masafumi; Ikeda, Minoru; Tomita, Hiroshi; Ikui, Akihiro; Aiba, Tsunemasa; Takeda, Noriaki; Inokuchi, Akira; Kurono, Yuichi; Nakashima, Mitsuyoshi; Shibasaki, Yuji; Yotsuya, Osamu

doi:10.1080/00016480802552550

Cited by 60 publications

(50 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1), has an anti-ulcer effect and is used clinically for the treatment of gastric ulcer in Japan (Matsukura and Tanaka 2000). Recently, Sakagami et al reported that polaprezinc improved hypogeusia without serious side effects in a well-controlled doubleblind clinical study (Sakagami et al 2008). We have also reported that polaprezinc ameliorated abnormalities of taste sensation in zincdeficient rats (Hamano et al 2006).…”

Section: Introductionsupporting

confidence: 58%

Polaprezinc, a zinc compound, is distributed to the lingual epithelium and increases its zinc concentration in zinc-deficient rats

et al. 2009

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 58%

Polaprezinc, a zinc compound, is distributed to the lingual epithelium and increases its zinc concentration in zinc-deficient rats

et al. 2009

View full text Add to dashboard Cite

“…It would be worthwhile to investigate in further studies if IBD patients with reduced olfactory and gustatory functions have improvements in their quality of life and in nutritional behavior when adding small amounts of herbs and spices (trigeminal input), glutamate, or other flavors to their foods [34]–[37]. Perhaps taste could be improved by prescribing oral zinc [38], [39].…”

Section: Discussionmentioning

confidence: 99%

Smell and Taste in Inflammatory Bowel Disease

et al. 2013

View full text Add to dashboard Cite

ObjectiveTo investigate the olfactory/gustatory functions of patients with inflammatory bowel disease (IBD) by smell/taste tests, and to determine if disease activity or medication might influence the olfactory/gustatory functions of patients.Patients and MethodsIn total, 59 IBD patients (37 Crohn's disease (CD) and 22 ulcerative colitis (UC) patients) were studied using “Sniffin' sticks” and “taste strips” for olfactory and gustatory tests, respectively, and compared to healthy controls and published normative data.ResultsAmong IBD (CD and UC) patients, the values for odor threshold, but not for odor identification or discrimination, were significantly lower than that of the normative data. Further, these patients showed lower values than the normative taste values and the control group for all tastes, except sour; 57.6% of the IBD patients were hyposmic, while 30.5% were hypogeusic. Subjective self-assessments showed that the patients were not aware of their reduced olfactory/gustatory functions. There were no relevant differences in taste and smell abilities between the CD and UC patients. Disease activity and treatment did not influence the olfactory/gustatory functions.ConclusionIBD (CD and UC) patients exhibited significant reductions in the olfactory and gustatory functions. Therefore, patients should be tested by smell/taste tests, in order to be adequately informed of their olfactory/gustatory functions and provided an understanding of how to overcome their limitations, and thus improve their quality of life.

show abstract

“…On the other hand, it has been demonstrated by a double‐blinded control clinical trial that PZ improves the disease conditions of idiopathic taste disorders 32. It has also been shown that zinc sulfate prevents taste alterations associated with radiation in patients with head and neck cancer,33 although inconsistent result showing no preventive effect of zinc sulfate against radiation‐induced taste alteration was also reported 34.…”

Section: Discussionmentioning

confidence: 99%

Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer

Watanabe

Ishihara

Matsuura

et al. 2010

Intl Journal of Cancer

View full text Add to dashboard Cite

Oral mucositis is frequent but serious adverse event associated with radiotherapy or radiochemotherapy in head and neck cancer severely impairs health-related quality of life, leading to poor prognosis due to discontinuation of the therapy. Although a number of compounds have been tested for prophylaxis of oral mucositis, few of them are satisfactory. We investigated the effect of polaprezinc (zinc L-carnosine), a gastric mucosal protective drug, on radiochemotherapy-induced oral mucositis, pain, xerostomia and taste disturbance in patients with head and neck cancer. Patients were randomly assigned to receive polaprezinc (n 5 16) or azulene oral rinse as the control (n 5 15). The incidence rates of mucositis, pain, xerostomia and taste disturbance were all markedly lower in polaprezinc group than in control. Moreover, the use of analgesics was significantly (p 5 0.003) less frequent and the amount of food intake was significantly (p 5 0.002) higher in polaprezinc group than in control. On the other hand, tumor response rate in patients with neoadjuvant radiochemotherapy was not significantly affected by polaprezinc, in which the response rate (complete plus partial response) was 88% for polaprezinc and 92% for control (p 5 1.000). Therefore, it is highly assumable that polaprezinc is potentially useful for prevention of oral mucositis and improvement of quality of life without reducing the tumor response.

show abstract

A zinc-containing compound, Polaprezinc, is effective for patients with taste disorders: randomized, double-blind, placebo-controlled, multi-center study

Cited by 60 publications

References 18 publications

Polaprezinc, a zinc compound, is distributed to the lingual epithelium and increases its zinc concentration in zinc-deficient rats

Polaprezinc, a zinc compound, is distributed to the lingual epithelium and increases its zinc concentration in zinc-deficient rats

Smell and Taste in Inflammatory Bowel Disease

Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer

Contact Info

Product

Resources

About